Qing Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Qing Zhou has a total of 469 co-authors. Here are the top co-authors by number of shared publications:
- Xiaomin Yu
Liangzhu Laboratory, Zhejiang University
24 shared publications Xu Han
State Key Laboratory of Common Mechanism Research for Major Diseases, Institute of Basic Medical Sciences & School of Basic Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
16 shared publicationsJun Wang
Liangzhu Laboratory of Zhejiang University, Department of Rheumatology, Sir Run Run Shaw Hospital Zhejiang University School of Medicine Hangzhou China
14 shared publicationsJiahui Zhang
National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China
13 shared publicationsChenlu Liu
Life Sciences Institute Zhejiang University Hangzhou China
11 shared publicationsLi Guo
Department of Rheumatology Immunology and Allergy, Children's Hospital, Zhejiang University School of Medicine, Hangzhou, China
11 shared publications
Latest Publications
- Open Access
- 14 October 2026
- Published by Caleo in Turkish Archives of Pediatrics
A Rare Case: Late-Onset STING-Associated Vasculopathy (STINGAssociated Vasculopathy with Onset in Infancy Syndrome) with Solely Lung Involvement
Turkish Archives of Pediatrics STING-associated vasculopathy with early onset, or STING-associated vasculopathy with onset in infancy (SAVI) syndrome (OMIM, Online Mendelian Inheritance in Man 615934; ORPHA: 425120) is an inherited, orphan autoinflammatory disease. It results from activating variants in the TMEM173 gene, which encodes the STING protein-a key regulator driving type I interferon responses. 1 The prevalence of SAVIs is estimated at approximately 1 in 1 million. 2 The disease usually begins in infancy but can present later. STING-associated vasculopathy with onset in infancy is marked by a clinical triad: it has a triad of symptoms: systemic inflammation, vasculopathy, and interstitial lung disease. Inflammation is characterized by fever and elevated acute-phase proteins, as well as antinuclear (ANA) and antineutrophil cytoplasmic antibody (ANCA) tests. Vasculopathies include erythema on the face and tip of the nose, distal ischemia, telangiectasias, nasal septal perforations, livedo rash, and Raynaud phenomenon. Interstitial lung diseases are seen in two-thirds of patients and pulmonary fibrosis in one-third. Other symptoms include myositis and fasciitis. The course and severity of lung disease vary even among patients with the same genetic variant. 3 There are overlapping features between SAVI syndrome, other rheumatic diseases, and the presence of autoantibodies, such as ANAs and ANCAs, which can lead to incorrect diagnosis and inappropriate treatment. The genetic confirmation of the TMEM173 sequence and the interferon signature can be useful for diagnosing SAVIs. However, outcomes are still poor, with approximately 20% of patients dying due to opportunistic infection, respiratory or heart failure. 3 Blocking type I interferons with Janus kinases appears to be promising compared to corticosteroids, cytotoxic drugs, and rituximab used in children. Fever episodes, skin rash, and systemic inflammation, with subsequent lung involvement in young children, are the main clinical features that allow us to suspect SAVI syndrome. Interstitial lung disease (ILD) as a sole presentation of SAVI is rare, and SAVI may remain undiagnosed for years in these cases. The aim of this report is to describe a late-onset SAVI case with ILD as the only presentation, and to provide literature data on the condition. A 16-year-old girl with mixed Russian (mother's) and Sudanese (father's) ethnicity, with no family history of inflammatory diseases (according to the talk with mother), including lung diseases, had shortness of breath that increased with physical activity, a dry cough, weight loss, and increased fatigue. She also had periodic joint pain. Chest computed tomography (CT) (first time in 15 years) revealed pronounced reticular changes in the pulmonary parenchymal architecture in all areas of the lungs (Figure 1A).
- 14 October 2026
- Published by Caleo in Turkish Archives of Pediatrics
Open AccessA Rare Case: Late-Onset STING-Associated Vasculopathy (STINGAssociated Vasculopathy with Onset in Infancy Syndrome) with Solely Lung Involvement
Turkish Archives of Pediatrics STING-associated vasculopathy with early onset, or STING-associated vasculopathy with onset in infancy (SAVI) syndrome (OMIM, Online Mendelian Inheritance in Man 615934; ORPHA: 425120) is an inherited, orphan autoinflammatory disease. It results from activating variants in the TMEM173 gene, which encodes the STING protein-a key regulator driving type I interferon responses. 1 The prevalence of SAVIs is estimated at approximately 1 in 1 million. 2 The disease usually begins in infancy but can present later. STING-associated vasculopathy with onset in infancy is marked by a clinical triad: it has a triad of symptoms: systemic inflammation, vasculopathy, and interstitial lung disease. Inflammation is characterized by fever and elevated acute-phase proteins, as well as antinuclear (ANA) and antineutrophil cytoplasmic antibody (ANCA) tests. Vasculopathies include erythema on the face and tip of the nose, distal ischemia, telangiectasias, nasal septal perforations, livedo rash, and Raynaud phenomenon. Interstitial lung diseases are seen in two-thirds of patients and pulmonary fibrosis in one-third. Other symptoms include myositis and fasciitis. The course and severity of lung disease vary even among patients with the same genetic variant. 3 There are overlapping features between SAVI syndrome, other rheumatic diseases, and the presence of autoantibodies, such as ANAs and ANCAs, which can lead to incorrect diagnosis and inappropriate treatment. The genetic confirmation of the TMEM173 sequence and the interferon signature can be useful for diagnosing SAVIs. However, outcomes are still poor, with approximately 20% of patients dying due to opportunistic infection, respiratory or heart failure. 3 Blocking type I interferons with Janus kinases appears to be promising compared to corticosteroids, cytotoxic drugs, and rituximab used in children. Fever episodes, skin rash, and systemic inflammation, with subsequent lung involvement in young children, are the main clinical features that allow us to suspect SAVI syndrome. Interstitial lung disease (ILD) as a sole presentation of SAVI is rare, and SAVI may remain undiagnosed for years in these cases. The aim of this report is to describe a late-onset SAVI case with ILD as the only presentation, and to provide literature data on the condition. A 16-year-old girl with mixed Russian (mother's) and Sudanese (father's) ethnicity, with no family history of inflammatory diseases (according to the talk with mother), including lung diseases, had shortness of breath that increased with physical activity, a dry cough, weight loss, and increased fatigue. She also had periodic joint pain. Chest computed tomography (CT) (first time in 15 years) revealed pronounced reticular changes in the pulmonary parenchymal architecture in all areas of the lungs (Figure 1A).
- Open Access
- 1 September 2026
- Published by Springer Nature in Cell Death & Disease
Cytotoxic lymphocyte death drives monocyte activation and TNF/IFN-γ synergism in TBK1 deficiency
TBK1 deficiency drives the pathogenesis of inborn errors of cell death (IECDs). However, the underlying cellular mechanisms remain unclear. Here, we identified a novel homozygous loss-of-function TBK1 variant resulting in exon 18 deletion (p.R621Sfs*21) that led to loss of TBK1 expression in a patient with systemic juvenile idiopathic arthritis (sJIA). The patient’s myeloid cells exhibited predominantly upregulated inflammatory responses, including TNF, NF-κB, and IFN (interferon)-γ signaling, while type I IFN responses were partially impaired in responses to agonists of pattern recognition receptors (PRRs). Analysis of the patient’s peripheral blood mononuclear cells (PBMCs) and healthy donor-derived TBK1 -knockout T cells showed that TBK1 -deficient cytotoxic lymphocytes are more susceptible to RIPK1-dependent cell death. Cell-cell communication analysis and combined treatment targeting TNF and IFN-γ highlighted a driving role of TNF/IFN-γ synergism in inflammatory activation of monocytes/T cells in the patient’s PBMCs, which was triggered by uncontrolled programmed cell death resulting from TBK1 deficiency. Long-term follow-up demonstrated that combined TNF and JAK inhibitor therapy was effective in suppressing the patient’s inflammatory responses. Our results identified a novel pathogenic TBK1 variant and demonstrated that cytotoxic lymphocytes are the primary drivers of aberrant cell death through a T cell-myeloid axis dependent on TNF/IFN-γ synergism. These results support combined TNF and JAK inhibition as an effective therapeutic strategy for TBK1 deficiency.
- 1 September 2026
- Published by Springer Nature in Cell Death & Disease
Open AccessCytotoxic lymphocyte death drives monocyte activation and TNF/IFN-γ synergism in TBK1 deficiency
TBK1 deficiency drives the pathogenesis of inborn errors of cell death (IECDs). However, the underlying cellular mechanisms remain unclear. Here, we identified a novel homozygous loss-of-function TBK1 variant resulting in exon 18 deletion (p.R621Sfs*21) that led to loss of TBK1 expression in a patient with systemic juvenile idiopathic arthritis (sJIA). The patient’s myeloid cells exhibited predominantly upregulated inflammatory responses, including TNF, NF-κB, and IFN (interferon)-γ signaling, while type I IFN responses were partially impaired in responses to agonists of pattern recognition receptors (PRRs). Analysis of the patient’s peripheral blood mononuclear cells (PBMCs) and healthy donor-derived TBK1 -knockout T cells showed that TBK1 -deficient cytotoxic lymphocytes are more susceptible to RIPK1-dependent cell death. Cell-cell communication analysis and combined treatment targeting TNF and IFN-γ highlighted a driving role of TNF/IFN-γ synergism in inflammatory activation of monocytes/T cells in the patient’s PBMCs, which was triggered by uncontrolled programmed cell death resulting from TBK1 deficiency. Long-term follow-up demonstrated that combined TNF and JAK inhibitor therapy was effective in suppressing the patient’s inflammatory responses. Our results identified a novel pathogenic TBK1 variant and demonstrated that cytotoxic lymphocytes are the primary drivers of aberrant cell death through a T cell-myeloid axis dependent on TNF/IFN-γ synergism. These results support combined TNF and JAK inhibition as an effective therapeutic strategy for TBK1 deficiency.
- 16 July 2026
- Published by Wiley in Arthritis & Rheumatology
A Multi‐Center Integrative Cohort Characterizing the Genetic, Clinical, and Transcriptomic Features of ACP5 Deficiency
Objectives: Spondyloenchondrodysplasia with immune dysregulation (SPENCDI) is a rare disorder caused by biallelic mutations in ACP5. This study systematically evaluates genetic landscape, clinical features, treatment, and transcriptomics in SPENCDI. Methods: Whole‐exome sequencing was performed for genetic diagnosis of patients from multiple centers, and tartrate‐resistant acid phosphatase (TRAP) activity was measured for novel variants. Previously reported cases were integrated with the current cohort for analysis of genotypes, clinical characteristics, laboratory findings, and treatment responses. Bulk and single‐cell RNA sequencing investigated immune signaling alterations. Results: We identified 17 patients with ACP5 deficiency from Egypt and China, discovering five novel pathogenic variants (A260D, L257P, G32D, K190Nfs*22, and T305Nfs*12). Three novel missense variants were detected with loss of TRAP activity. Clinical manifestations involve multiple systems, with the skeletal system most frequently involved (32.31%), where skeletal dysplasia (94.32%) and short stature (81.82%) are the predominant features. Patients showed elevated inflammatory activity, with enrichment of the NF‐κB, MAPK, and cell death pathways, as well as upregulation of type I interferon genes in monocytes. Enhanced IFN‐γ signaling interactions between monocytes and Natural Killer cells were observed. Therapeutically, Prednisolone and Azathioprine were the most common effective drugs, while patients treated with the Janus kinase inhibitors Ruxolitinib or Upadacitinib achieved a partial response. Conclusions: This study expanded the genetic and clinical spectrum of ACP5 deficiency. An upregulated interferon signature was revealed, and monocytes were identified as a major cellular source of inflammation. These results provide valuable insights for improving the diagnosis and treatment of SPENCDI.
- 16 July 2026
- Published by Wiley in Arthritis & Rheumatology
A Multi‐Center Integrative Cohort Characterizing the Genetic, Clinical, and Transcriptomic Features of ACP5 Deficiency
Objectives: Spondyloenchondrodysplasia with immune dysregulation (SPENCDI) is a rare disorder caused by biallelic mutations in ACP5. This study systematically evaluates genetic landscape, clinical features, treatment, and transcriptomics in SPENCDI. Methods: Whole‐exome sequencing was performed for genetic diagnosis of patients from multiple centers, and tartrate‐resistant acid phosphatase (TRAP) activity was measured for novel variants. Previously reported cases were integrated with the current cohort for analysis of genotypes, clinical characteristics, laboratory findings, and treatment responses. Bulk and single‐cell RNA sequencing investigated immune signaling alterations. Results: We identified 17 patients with ACP5 deficiency from Egypt and China, discovering five novel pathogenic variants (A260D, L257P, G32D, K190Nfs*22, and T305Nfs*12). Three novel missense variants were detected with loss of TRAP activity. Clinical manifestations involve multiple systems, with the skeletal system most frequently involved (32.31%), where skeletal dysplasia (94.32%) and short stature (81.82%) are the predominant features. Patients showed elevated inflammatory activity, with enrichment of the NF‐κB, MAPK, and cell death pathways, as well as upregulation of type I interferon genes in monocytes. Enhanced IFN‐γ signaling interactions between monocytes and Natural Killer cells were observed. Therapeutically, Prednisolone and Azathioprine were the most common effective drugs, while patients treated with the Janus kinase inhibitors Ruxolitinib or Upadacitinib achieved a partial response. Conclusions: This study expanded the genetic and clinical spectrum of ACP5 deficiency. An upregulated interferon signature was revealed, and monocytes were identified as a major cellular source of inflammation. These results provide valuable insights for improving the diagnosis and treatment of SPENCDI.
- 27 May 2026
- Published by Wiley in Arthritis & Rheumatology
- Vol. 78 (10) , 2181-2182
Reply
- Open Access
- 21 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
IRAK2 deficiency causes immune dysregulation through defective Myddosome assembly and enhanced interferon responses
Interleukin-1 receptor-associated kinase 2 (IRAK2) is essential for the Myddosome complex formation downstream of Toll-like receptors. We identify twelve patients with a homozygous loss-of-function copy number variant in IRAK2, designated IRAK2-∆ex2. Most patients present with recurrent infections, autoantibody production, and gastrointestinal ulceration. Two patients were clinically diagnosed with primary immunodeficiency, while the majority fulfill diagnostic criteria for autoimmune or autoinflammatory diseases. The IRAK2-∆ex2 protein fails to interact with IRAK4, leading to impaired activation of nuclear factor kappa B signaling via the Myddosome complex. An elevated type I interferon signature is observed in the patients, which is confirmed in bone marrow-derived macrophages from knock-in mice and knockout cell lines. Mechanistically, our data are consistent with engagement of a TRIF-dependent interferon pathway. Baricitinib attenuates the elevated interferon signature in patient-derived cells ex vivo and cell lines. Here, we show IRAK2 deficiency as a monogenic immune dysregulation disorder.
- 21 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessIRAK2 deficiency causes immune dysregulation through defective Myddosome assembly and enhanced interferon responses
Interleukin-1 receptor-associated kinase 2 (IRAK2) is essential for the Myddosome complex formation downstream of Toll-like receptors. We identify twelve patients with a homozygous loss-of-function copy number variant in IRAK2, designated IRAK2-∆ex2. Most patients present with recurrent infections, autoantibody production, and gastrointestinal ulceration. Two patients were clinically diagnosed with primary immunodeficiency, while the majority fulfill diagnostic criteria for autoimmune or autoinflammatory diseases. The IRAK2-∆ex2 protein fails to interact with IRAK4, leading to impaired activation of nuclear factor kappa B signaling via the Myddosome complex. An elevated type I interferon signature is observed in the patients, which is confirmed in bone marrow-derived macrophages from knock-in mice and knockout cell lines. Mechanistically, our data are consistent with engagement of a TRIF-dependent interferon pathway. Baricitinib attenuates the elevated interferon signature in patient-derived cells ex vivo and cell lines. Here, we show IRAK2 deficiency as a monogenic immune dysregulation disorder.
- Open Access
- 28 April 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (18)
TLR1 deficiency associates with immune dysregulation and colitis
Toll-like receptor 1 (TLR1), a member of the TLR family, assumes a pivotal role in pathogen recognition and the activation of innate immunity. In this study, we have identified a homozygous truncating TLR1 variant associated with immune dysregulation and colitis. Peripheral blood mononuclear cells derived from the patient manifested robust inflammatory signatures and defective TLR1 signaling responses. TLR1-deficient cells demonstrated impaired production of a wide-spectrum of inflammatory cytokines, antimicrobial peptides, and the anti-inflammatory cytokine IL-10 following stimulation with TLR1 ligand. This defect culminated in impaired bactericidal activity and dysregulated termination of the inflammatory response, especially characterized by a significant enhancement of the CXCR3 signaling pathway. TLR1-KO mice exhibited increased susceptibility to Salmonella Typhimurium infection and dextran sulfate sodium-induced colitis, with augmented infiltration of monocytes and macrophages in the pathological colon. The administration of IL-10 significantly alleviated the colitis phenotype associated with TLR1 deficiency in mice. This investigation underscores the crucial function of TLR1 in orchestrating a context-appropriate immune response to microbial invasion while averting excessive inflammation, thereby highlighting its indispensable role in human physiology and disease.
- 28 April 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (18)
Open AccessTLR1 deficiency associates with immune dysregulation and colitis
Toll-like receptor 1 (TLR1), a member of the TLR family, assumes a pivotal role in pathogen recognition and the activation of innate immunity. In this study, we have identified a homozygous truncating TLR1 variant associated with immune dysregulation and colitis. Peripheral blood mononuclear cells derived from the patient manifested robust inflammatory signatures and defective TLR1 signaling responses. TLR1-deficient cells demonstrated impaired production of a wide-spectrum of inflammatory cytokines, antimicrobial peptides, and the anti-inflammatory cytokine IL-10 following stimulation with TLR1 ligand. This defect culminated in impaired bactericidal activity and dysregulated termination of the inflammatory response, especially characterized by a significant enhancement of the CXCR3 signaling pathway. TLR1-KO mice exhibited increased susceptibility to Salmonella Typhimurium infection and dextran sulfate sodium-induced colitis, with augmented infiltration of monocytes and macrophages in the pathological colon. The administration of IL-10 significantly alleviated the colitis phenotype associated with TLR1 deficiency in mice. This investigation underscores the crucial function of TLR1 in orchestrating a context-appropriate immune response to microbial invasion while averting excessive inflammation, thereby highlighting its indispensable role in human physiology and disease.
- 14 April 2026
- Published by Wiley in Arthritis & Rheumatology
- Vol. 78 (9) , 1975-1988
Landscape of Somatic Mutations in a Large Cohort of Chinese Patients With Immune Dysregulations
Objective: This study aims to characterize pathogenic somatic mutations in patients with autoinflammatory or autoimmune diseases lacking disease‐causing germline mutations, explore their contribution to disease pathogenesis and progression, and evaluate their implications for diagnosis and targeted therapy. Methods: We performed a systematic analysis of somatic mutations in a selected panel of 185 immune‐related genes in 2,912 patients with autoinflammatory or autoimmune diseases, recruited from 41 medical centers across China, who were previously negative for germline mutations based on whole‐exome sequencing. Results: We identified both previously reported and novel somatic mutations in genes such as UBA1 , KRAS , and NLRP3 . Pathogenic somatic mutations in TNFAIP3 were discovered first in patients with autoinflammatory diseases. The pathogenic somatic mutation detection rate was 1.35% in adults and 0.97% in children, emphasizing the importance of genetic diagnosis and novel gene discovery for somatic mutations. In addition, somatic mutations in Ras‐related genes were identified in seven patients, and 39 clonal hematopoiesis–associated mutations were identified in 36 adult patients. Moreover, myeloid cells harboring somatic mutations expanded during disease flare and reduced during remission. Disregarding the dynamic elevation of the variant allele fraction during disease progression led to therapeutic failure. Conclusion: This study delineated the genetic landscape of pathogenic somatic mutations underlying autoinflammatory and autoimmune diseases, offering valuable insights for genetic diagnosis and targeted therapies.
- 14 April 2026
- Published by Wiley in Arthritis & Rheumatology
- Vol. 78 (9) , 1975-1988
Landscape of Somatic Mutations in a Large Cohort of Chinese Patients With Immune Dysregulations
Objective: This study aims to characterize pathogenic somatic mutations in patients with autoinflammatory or autoimmune diseases lacking disease‐causing germline mutations, explore their contribution to disease pathogenesis and progression, and evaluate their implications for diagnosis and targeted therapy. Methods: We performed a systematic analysis of somatic mutations in a selected panel of 185 immune‐related genes in 2,912 patients with autoinflammatory or autoimmune diseases, recruited from 41 medical centers across China, who were previously negative for germline mutations based on whole‐exome sequencing. Results: We identified both previously reported and novel somatic mutations in genes such as UBA1 , KRAS , and NLRP3 . Pathogenic somatic mutations in TNFAIP3 were discovered first in patients with autoinflammatory diseases. The pathogenic somatic mutation detection rate was 1.35% in adults and 0.97% in children, emphasizing the importance of genetic diagnosis and novel gene discovery for somatic mutations. In addition, somatic mutations in Ras‐related genes were identified in seven patients, and 39 clonal hematopoiesis–associated mutations were identified in 36 adult patients. Moreover, myeloid cells harboring somatic mutations expanded during disease flare and reduced during remission. Disregarding the dynamic elevation of the variant allele fraction during disease progression led to therapeutic failure. Conclusion: This study delineated the genetic landscape of pathogenic somatic mutations underlying autoinflammatory and autoimmune diseases, offering valuable insights for genetic diagnosis and targeted therapies.
- 26 March 2026
- Published by Wiley in Arthritis & Rheumatology
- Vol. 78 (6) , 1306-1317
Deficiency of AP1M2 Causes a New Autoinflammatory Disease With Colitis
Objective: This study was the first to identify the biallelic loss‐of‐function variant in AP1M2 as the cause of autoinflammatory disease with colitis and aimed to elucidate the pathogenesis of AP1M2 deficiency in mice and humans. Methods: We collected a blood sample and serum sample from a patient for genetic diagnosis and determination of inflammatory cytokines, respectively. Ap1m2 ‐deficient mice on the C57BL/6 background and DLD‐1 cells were used to dissect the functional role of Ap1m2 in serum and intestines. Stereo‐seq was performed on Ap1m2 −/− and Ap1m2 −/− :: Tnfr1 −/− mouse samples to investigate the regulatory role of Tnfr1 signaling in the pathogenesis of Ap1m2 deficiency–caused intestinal inflammation. Superrevolution imaging and clathrin‐coated vesicle enrichment were used to explore the molecular mechanism by which AP1M2 suppresses NF‐κB activation and chemokine production. Results: Ap1m2 −/− mice exhibited elevated chemokine production in serum and spontaneously developed intestinal inflammation, which phenocopies the patient with the AP1M2 variant. Mechanistically, the deficiency of intestinal epithelial specific AP1M2 expression resulted in accumulation of TNFR1‐signaling downstream proteins, including RIPK1, TBK1, IKKα/β, and NEMO, leading to enhanced NF‐κB activation and subsequent chemokine overproduction. Tnfr1 knockout rescued gastrointestinal inflammation induced by Ap1m2 deficiency through suppressing NF‐κB activation and chemokine production. Conclusion: This study identifies the deficiency of AP1M2 as the cause of a new autoinflammatory disease with colitis and highlights the critical function of AP‐1 in suppressing NF‐κB activation and chemokine production. image
- 26 March 2026
- Published by Wiley in Arthritis & Rheumatology
- Vol. 78 (6) , 1306-1317
Deficiency of AP1M2 Causes a New Autoinflammatory Disease With Colitis
Objective: This study was the first to identify the biallelic loss‐of‐function variant in AP1M2 as the cause of autoinflammatory disease with colitis and aimed to elucidate the pathogenesis of AP1M2 deficiency in mice and humans. Methods: We collected a blood sample and serum sample from a patient for genetic diagnosis and determination of inflammatory cytokines, respectively. Ap1m2 ‐deficient mice on the C57BL/6 background and DLD‐1 cells were used to dissect the functional role of Ap1m2 in serum and intestines. Stereo‐seq was performed on Ap1m2 −/− and Ap1m2 −/− :: Tnfr1 −/− mouse samples to investigate the regulatory role of Tnfr1 signaling in the pathogenesis of Ap1m2 deficiency–caused intestinal inflammation. Superrevolution imaging and clathrin‐coated vesicle enrichment were used to explore the molecular mechanism by which AP1M2 suppresses NF‐κB activation and chemokine production. Results: Ap1m2 −/− mice exhibited elevated chemokine production in serum and spontaneously developed intestinal inflammation, which phenocopies the patient with the AP1M2 variant. Mechanistically, the deficiency of intestinal epithelial specific AP1M2 expression resulted in accumulation of TNFR1‐signaling downstream proteins, including RIPK1, TBK1, IKKα/β, and NEMO, leading to enhanced NF‐κB activation and subsequent chemokine overproduction. Tnfr1 knockout rescued gastrointestinal inflammation induced by Ap1m2 deficiency through suppressing NF‐κB activation and chemokine production. Conclusion: This study identifies the deficiency of AP1M2 as the cause of a new autoinflammatory disease with colitis and highlights the critical function of AP‐1 in suppressing NF‐κB activation and chemokine production. image
- Open Access
- 12 March 2026
- Published by Wiley in Arthritis & Rheumatology
- Vol. 78 (6) , 1318-1326
OGFRL1 Deficiency Causes Chronic Recurrent Multifocal Osteomyelitis Via Pathologic Osteoclastogenesis, With Therapeutic Response to Tumor Necrosis Factor Inhibitor
Objective: To verify the pathogenesis of the opioid growth factor receptor like‐1 ( OGFRL1) loss‐of‐function variant (c.30del, p. F10Ffs*110) identified in a patient with chronic recurrent multifocal osteomyelitis (CRMO) and to investigate the underlying mechanism. Methods: Whole exome sequencing and Sanger sequencing were performed to identify and confirm the variant. Quantitative polymerase chain reaction, enzyme‐linked immunosorbent assay, cytometric bead assay, bulk RNA sequencing, and single‐cell RNA sequencing were conducted to detect the inflammatory signatures of the patient versus healthy controls. A collagen antibody–induced arthritis (CAIA) model was generated in Ogfrl1 knockout (KO) and wild type (WT) mice, and micro–computed tomography scan was performed to investigate the pathogenicity of Ogfrl1 deficiency. In addition, osteoclast induction and differentiation in vitro was exerted to explore the underlying mechanism of Ogfrl1 deficiency. Results: The patient exhibited up‐regulated mitogen‐activated protein kinase (MAPK) and NF‐κB signaling pathways, along with overproduction of pro‐inflammatory cytokines. Compared to healthy controls, apparent activation of myeloid cells was observed, especially in monocytes, dendritic cells, and low‐density granulocytes (LDGs) of the patient. In the CAIA model, Ogfrl1 KO mice developed more severe and persistent arthritis and bone erosion than WT mice. Ogfrl1 KO mice were more prone to osteoclast differentiation than WT mice. The patient responded well to tumor necrosis factor inhibitor therapy, with normalization of C‐reactive protein levels, erythrocyte sedimentation rate, serum amyloid A levels, and interleukin‐6 levels, as well as improvement in osteolytic lesions. Conclusion: This study identified OGFRL1 deficiency as a novel cause of CRMO, highlighted the previously unrecognized role of OGFRL1 in restraining inflammatory responses, and provided novel insights into the pathogenesis and treatment of this autoinflammatory disorder.
- 12 March 2026
- Published by Wiley in Arthritis & Rheumatology
- Vol. 78 (6) , 1318-1326
Open AccessOGFRL1 Deficiency Causes Chronic Recurrent Multifocal Osteomyelitis Via Pathologic Osteoclastogenesis, With Therapeutic Response to Tumor Necrosis Factor Inhibitor
Objective: To verify the pathogenesis of the opioid growth factor receptor like‐1 ( OGFRL1) loss‐of‐function variant (c.30del, p. F10Ffs*110) identified in a patient with chronic recurrent multifocal osteomyelitis (CRMO) and to investigate the underlying mechanism. Methods: Whole exome sequencing and Sanger sequencing were performed to identify and confirm the variant. Quantitative polymerase chain reaction, enzyme‐linked immunosorbent assay, cytometric bead assay, bulk RNA sequencing, and single‐cell RNA sequencing were conducted to detect the inflammatory signatures of the patient versus healthy controls. A collagen antibody–induced arthritis (CAIA) model was generated in Ogfrl1 knockout (KO) and wild type (WT) mice, and micro–computed tomography scan was performed to investigate the pathogenicity of Ogfrl1 deficiency. In addition, osteoclast induction and differentiation in vitro was exerted to explore the underlying mechanism of Ogfrl1 deficiency. Results: The patient exhibited up‐regulated mitogen‐activated protein kinase (MAPK) and NF‐κB signaling pathways, along with overproduction of pro‐inflammatory cytokines. Compared to healthy controls, apparent activation of myeloid cells was observed, especially in monocytes, dendritic cells, and low‐density granulocytes (LDGs) of the patient. In the CAIA model, Ogfrl1 KO mice developed more severe and persistent arthritis and bone erosion than WT mice. Ogfrl1 KO mice were more prone to osteoclast differentiation than WT mice. The patient responded well to tumor necrosis factor inhibitor therapy, with normalization of C‐reactive protein levels, erythrocyte sedimentation rate, serum amyloid A levels, and interleukin‐6 levels, as well as improvement in osteolytic lesions. Conclusion: This study identified OGFRL1 deficiency as a novel cause of CRMO, highlighted the previously unrecognized role of OGFRL1 in restraining inflammatory responses, and provided novel insights into the pathogenesis and treatment of this autoinflammatory disorder.
- Open Access
- 11 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
CD8+ T cell loss induces autoinflammation in inborn errors of cell death
Systemic autoinflammatory diseases (SAID) with inborn errors of cell death (IECD) are caused by overactivation of programmed cell death (PCD). However, the pathogenesis by which PCD leads to autoinflammation remains unclear. Here, we identified IECD patients carrying compound heterozygous RIPK1 variants K377E/R390G with autoinflammatory manifestations. Mechanistically, K377E and R390G mutations suppress NF-κB signaling and activate RIPK1 to promote cell death. CD8+ T cells of the patients displayed overactivated RIPK1 and excessive cell death, leading to an elevated CD4/CD8 ratio, which could also be detected in patients with cleavage-resistant mutation of RIPK1 or SHARPIN deficiency. We show that the increased cell death of CD8+ T cells promotes TNF and IFN-γ secretion to activate monocytes/macrophages, which triggers overproduction of proinflammatory cytokines. In addition, disruption of the communication between T cells and monocytes/macrophages through pharmacologic blockade of TNF and IFN attenuates proinflammatory cytokine production in macrophages and relieves all the symptoms in patients. This study further clarifies the mechanism for a group of IECD with SAID. Increased CD4/CD8 ratio and augmented RIPK1 activation in T cells provide potentially additional criteria for diagnosis of RIPK1-dependent IECD and a combination of TNF/JAK inhibitor could be an effective therapy for the diagnosed patients.
- 11 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessCD8+ T cell loss induces autoinflammation in inborn errors of cell death
Systemic autoinflammatory diseases (SAID) with inborn errors of cell death (IECD) are caused by overactivation of programmed cell death (PCD). However, the pathogenesis by which PCD leads to autoinflammation remains unclear. Here, we identified IECD patients carrying compound heterozygous RIPK1 variants K377E/R390G with autoinflammatory manifestations. Mechanistically, K377E and R390G mutations suppress NF-κB signaling and activate RIPK1 to promote cell death. CD8+ T cells of the patients displayed overactivated RIPK1 and excessive cell death, leading to an elevated CD4/CD8 ratio, which could also be detected in patients with cleavage-resistant mutation of RIPK1 or SHARPIN deficiency. We show that the increased cell death of CD8+ T cells promotes TNF and IFN-γ secretion to activate monocytes/macrophages, which triggers overproduction of proinflammatory cytokines. In addition, disruption of the communication between T cells and monocytes/macrophages through pharmacologic blockade of TNF and IFN attenuates proinflammatory cytokine production in macrophages and relieves all the symptoms in patients. This study further clarifies the mechanism for a group of IECD with SAID. Increased CD4/CD8 ratio and augmented RIPK1 activation in T cells provide potentially additional criteria for diagnosis of RIPK1-dependent IECD and a combination of TNF/JAK inhibitor could be an effective therapy for the diagnosed patients.